Roivant Sciences Ltd. (ROIVW)
2.75
0.12 (4.56%)
Jan 16, 2025, 9:00 PM - Market open
4.56% (1D)
| Bid | n/a |
| Market Cap | 7.83B |
| Revenue (ttm) | 97.56M |
| Net Income (ttm) | -116.62M |
| EPS (ttm) | -4.092 |
| PE Ratio (ttm) | -0.6720430107526881 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 37,827 |
| Avg. Volume (20D) | 37,827 |
| Open | 2.86 |
| Previous Close | 2.63 |
| Day's Range | 2.63 - 2.86 |
| 52-Week Range | 2.63 - 2.86 |
| Beta | 0.00 |
About ROIVW
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2021
Employees 620
Stock Exchange NASDAQ
Ticker Symbol ROIVW
Website http://roivant.com